A Multicenter Prospective Study on Efficacy and Safety of Ponatinib in Patients with Chronic Myeloid Leukemia Resistant or Intolerant to Previous Therapy: A 3-Year Report
Tomasz Sacha, Olga Grzybowska‐Izydorczyk, Monika Joks(Poznan University of Medical Sciences), Aleksandra Kostyra(Provincial Polyclinical Hospital in Toruń), Joanna Wasilewska(Instytut Hematologii i Transfuzjologi), Marta Oller, Joanna Niesiobędzka‐Krężel(Medical University of Warsaw), Witold Prejzner(Gdańsk Medical University), Renata Kroll‐Balcerzak(Poznan University of Medical Sciences), Anna Rudkowska-Kazanowska(Medical University of Silesia), Janusz Kłoczko(University Clinical Hospital In Bialystok), Elżbieta Patkowska(Institute for Transfusion Medicine), Małgorzata Wach(Medical University of Lublin), Joanna Góra‐Tybor, Magdalena Świniarska(Pomeranian Medical University), Tomasz Gromek(Medical University of Lublin), Edyta Paczkowska(Pomeranian Medical University), Paulina Dumnicka(Jagiellonian University), Ryszard Wichary(Medical University of Silesia), Justyna Gil(Lublin Oncology Center), Renata Kasza(State Higher School of Vocational Education in Zamość), Hanna Ciepłuch, Ewa Mędraś(Wroclaw Medical University), Małgorzata Kopera(Medical University of Silesia), Grażyna Bober(Medical University of Silesia), Elżbieta Szczepanek(Jagiellonian University), Wioletta Makowska(Instytut Hematologii i Transfuzjologi), Ewa Wasilewska(Medical University of Silesia)
Cited by 1